| scholarly article | Q13442814 |
| P356 | DOI | 10.1086/339963 |
| P698 | PubMed publication ID | 11930311 |
| P2093 | author name string | Paul A H Moss | |
| Mark Cobbold | |||
| Naeem Khan | |||
| Russell Keenan | |||
| P433 | issue | 8 | |
| P921 | main subject | phenotype | Q104053 |
| P304 | page(s) | 1025-1034 | |
| P577 | publication date | 2002-03-25 | |
| P1433 | published in | Journal of Infectious Diseases | Q4051141 |
| P1476 | title | Comparative analysis of CD8+ T cell responses against human cytomegalovirus proteins pp65 and immediate early 1 shows similarities in precursor frequency, oligoclonality, and phenotype | |
| P478 | volume | 185 |
| Q40627421 | A CTL epitope from human cytomegalovirus IE1 defined by combining prediction of HLA binding and proteasomal processing is the target of dominant immune responses in patients after allogeneic stem cell transplantation |
| Q36960167 | A cytomegalovirus inhibitor of gamma interferon signaling controls immunoproteasome induction |
| Q36005476 | A cytomegalovirus-based vaccine expressing a single tumor-specific CD8+ T-cell epitope delays tumor growth in a murine model of prostate cancer |
| Q36824066 | A fusion protein of HCMV IE1 exon4 and IE2 exon5 stimulates potent cellular immunity in an MVA vaccine vector. |
| Q36960608 | A novel approach to evaluate the immunogenicity of viral antigens of clinical importance in HLA transgenic murine models |
| Q78471193 | Antigens and immunoevasins: opponents in cytomegalovirus immune surveillance |
| Q37837483 | Bias in the αβ T-cell repertoire: implications for disease pathogenesis and vaccination |
| Q37082145 | Broad cross-reactive TCR repertoires recognizing dissimilar Epstein-Barr and influenza A virus epitopes. |
| Q55259946 | Clinical-grade generation of peptide-stimulated CMV/EBV-specific T cells from G-CSF mobilized stem cell grafts. |
| Q38856032 | Coinfection with Human Cytomegalovirus Genetic Variants in Transplant Recipients and Its Impact on Antiviral T Cell Immune Reconstitution |
| Q27487966 | Comparisons of CD8+ T Cells Specific for Human Immunodeficiency Virus, Hepatitis C Virus, and Cytomegalovirus Reveal Differences in Frequency, Immunodominance, Phenotype, and Interleukin-2 Responsiveness |
| Q34584683 | Cross-reactive anti-viral T cells increase prior to an episode of viral reactivation post human lung transplantation |
| Q35020384 | Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein. |
| Q47101572 | Cytomegalovirus (CMV) immune monitoring with ELISPOT and QuantiFERON-CMV assay in seropositive kidney transplant recipients |
| Q35922928 | Cytomegalovirus in hematopoietic stem cell transplant recipients |
| Q38703120 | Cytomegalovirus infection in hematologic malignancy settings other than the allogeneic transplant. |
| Q47221262 | Cytomegalovirus-Specific T Cells Restricted by HLA-Cw*0702 Increase Markedly with Age and Dominate the CD8+ T-Cell Repertoire in Older People. |
| Q35958856 | Determinants of public T cell responses |
| Q34788895 | Development of a novel, guinea pig-specific IFN-γ ELISPOT assay and characterization of guinea pig cytomegalovirus GP83-specific cellular immune responses following immunization with a modified vaccinia virus Ankara (MVA)-vectored GP83 vaccine |
| Q34262249 | Diverse specificities, phenotypes, and antiviral activities of cytomegalovirus-specific CD8+ T cells |
| Q37095344 | Dynamics of T cell memory in human cytomegalovirus infection |
| Q101237609 | Early emergence of T central memory precursors programs clonal dominance during chronic viral infection |
| Q36953959 | Expansion of protective CD8+ T-cell responses driven by recombinant cytomegaloviruses |
| Q34777218 | Expression of cutaneous lymphocyte-associated antigen by CD8(+) T cells specific for a skin-tropic virus |
| Q34594928 | Expression of the human cytomegalovirus UL11 glycoprotein in viral infection and evaluation of its effect on virus-specific CD8 T cells |
| Q92516044 | Generation, maintenance and tissue distribution of T cell responses to human cytomegalovirus in lytic and latent infection |
| Q36086786 | Genetic analysis of cytomegalovirus in malignant gliomas |
| Q36484918 | HLA-DR and HLA-DP restricted epitopes from human cytomegalovirus glycoprotein B recognized by CD4+ T-cell clones from chronically infected individuals. |
| Q33755031 | Highly protective in vivo function of cytomegalovirus IE1 epitope-specific memory CD8 T cells purified by T-cell receptor-based cell sorting |
| Q37807749 | Human cytomegalovirus immunity and immune evasion |
| Q35018043 | Human cytomegalovirus latency-associated proteins elicit immune-suppressive IL-10 producing CD4⁺ T cells |
| Q38758389 | Human cytomegalovirus miR-UL112-1 promotes the down-regulation of viral immediate early-gene expression during latency to prevent T-cell recognition of latently infected cells. |
| Q43813634 | Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia |
| Q35558537 | Human cytomegalovirus-specific immunity following haemopoietic stem cell transplantation |
| Q35965038 | Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments. |
| Q35156297 | Identification and HLA-tetramer-validation of human CD4+ and CD8+ T cell responses against HCMV proteins IE1 and IE2. |
| Q92206244 | Identification of HCMV-derived T cell epitopes in seropositive individuals through viral deletion models |
| Q41057170 | Identification of cytomegalovirus-specific cytotoxic T lymphocytes in vitro is greatly enhanced by the use of recombinant virus lacking the US2 to US11 region or modified vaccinia virus Ankara expressing individual viral genes |
| Q37050965 | Immunobiology of human cytomegalovirus: from bench to bedside. |
| Q97879068 | Immunophenotyping of rhesus CMV-specific CD8 T Cell Populations |
| Q41979810 | Immunosequencing identifies signatures of cytomegalovirus exposure history and HLA-mediated effects on the T cell repertoire |
| Q37006823 | Immunotherapeutic strategies to prevent and treat human herpesvirus 6 reactivation after allogeneic stem cell transplantation |
| Q37148739 | Impact of cytomegalovirus and grafts versus host disease on the dynamics of CD57+CD28-CD8+ T cells after bone marrow transplant |
| Q35661383 | Latent Membrane Protein LMP2A Impairs Recognition of EBV-Infected Cells by CD8+ T Cells |
| Q36835155 | Long-term expansion of effector/memory Vdelta2-gammadelta T cells is a specific blood signature of CMV infection |
| Q41862309 | Memory inflation during chronic viral infection is maintained by continuous production of short-lived, functional T cells. |
| Q33653229 | Modified H5 promoter improves stability of insert genes while maintaining immunogenicity during extended passage of genetically engineered MVA vaccines |
| Q60913862 | Mouse Model of Cytomegalovirus Disease and Immunotherapy in the Immunocompromised Host: Predictions for Medical Translation that Survived the "Test of Time" |
| Q51040397 | Persistent viral infection in humans can drive high frequency low-affinity T-cell expansions. |
| Q92882797 | Precision mouse models with expanded tropism for human pathogens |
| Q42151049 | Predictable alphabeta T-cell receptor selection toward an HLA-B*3501-restricted human cytomegalovirus epitope |
| Q34743762 | Presentation of an immunodominant immediate-early CD8+ T cell epitope resists human cytomegalovirus immunoevasion |
| Q35945705 | Prevention of maternal and congenital cytomegalovirus infection |
| Q34338725 | Profile of a Serial Killer: Cellular and Molecular Approaches to Study Individual Cytotoxic T‐Cells following Therapeutic Vaccination |
| Q90615815 | Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax |
| Q47564568 | Relative dominance of HLA-B*07 restricted CD8+ T-lymphocyte immune responses to human cytomegalovirus pp65 in persons sharing HLA-A*02 and HLA-B*07 alleles |
| Q46786257 | Safety and immunogenicity of Towne cytomegalovirus vaccine with or without adjuvant recombinant interleukin-12. |
| Q33217629 | Selection of CMV-specific CD8+ and CD4+ T cells by mini-EBV-transformed B cell lines |
| Q38815977 | T cell responses to cytomegalovirus |
| Q36594211 | The early kinetics of cytomegalovirus-specific CD8+ T-cell responses are not affected by antigen load or the absence of perforin or gamma interferon |
| Q38716767 | The essential role of guinea pig cytomegalovirus (GPCMV) IE1 and IE2 homologs in viral replication and IE1-mediated ND10 targeting |
| Q36115162 | The immunological footprint of CMV in HIV-1 patients stable on long-term ART |
| Q36673919 | The interplay between host and viral factors in shaping the outcome of cytomegalovirus infection |
| Q37095250 | The molecular basis for public T-cell responses? |
| Q38049899 | The next generation recombinant human cytomegalovirus vaccine candidates-beyond gB. |
| Q55082270 | Tissue maintenance of CMV-specific inflationary memory T cells by IL-15. |
| Q42938727 | Tonsillar homing of Epstein-Barr virus-specific CD8+ T cells and the virus-host balance |
| Q54321271 | Transfection of dendritic cells with in vitro-transcribed CMV RNA induces polyclonal CD8+- and CD4+-mediated CMV-specific T cell responses. |
| Q34782568 | Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response |
| Q36299933 | Validation of T-Track® CMV to assess the functionality of cytomegalovirus-reactive cell-mediated immunity in hemodialysis patients |
Search more.